08:00 , Mar 4, 2013 |  BC Week In Review  |  Company News

Aros Applied Biotechnology A/S, Eurofins deal

Genomic services company Eurofins announced the acquisition of next-generation sequencing company Aros. Eurofins said Aros generates revenues of about €10 million ($13.4 million). Eurofins reported €751.1 million ($965.6 million) in revenue for the first nine...
08:00 , Dec 24, 2012 |  BioCentury  |  Emerging Company Profile

Aros: Easing IBS pain

Aros Pharma ApS has found a new way to treat pain associated with irritable bowel syndrome. The company is developing an ASIC1A antagonist that specifically reduces gastrointestinal pain and could be an effective adjunct therapy...
07:00 , Sep 18, 2006 |  BC Week In Review  |  Company News

Aros Applied Biotechnology, Stratagene deal

Aros granted STGN an exclusive option to evaluate and license patents and patent applications covering a family of gene expression predictors for bladder cancer. Financial terms were not disclosed. Aros Applied Biotechnology , Aarhus, Demark...
07:00 , Jun 26, 2000 |  BioCentury  |  Finance

A little quirky

Europe provided a flurry of IPO activity . including an eyebrow raising turnabout and a deal headed for the U.S. to go along with a couple of over-subscribed closings. Investors were taken by surprise when...
07:00 , Jun 20, 2000 |  BC Extra  |  Financial News

European IPO updates

Activity surrounding the European IPO window was mixed on Tuesday, with one company on the Continent announcing intentions to list and another postponing its public offering. MediGene (Martinsried, Germany), the cancer and cardiovascular drug discovery...
07:00 , Jun 12, 2000 |  BioCentury  |  Finance

Ebb & Flow

IPO overallotment sales are closely watched on Wall Street as a barometer of investor appetite for a new security. So perhaps it doesn't bode well that underwriters for the last two biotech IPOs couldn't fill...
07:00 , Jun 7, 2000 |  BC Extra  |  Financial News

Personal Chemistry seeks IPO

Personal Chemistry (Uppsala, Sweden), which is developing microwave-assisted chemical synthesis technology, said it hopes to raise SEK 454 million ($51.4 million) through the sale of 4.3 million shares between SEK75 and SEK105 in an IPO...
07:00 , Jun 5, 2000 |  BioCentury  |  Finance

Spring loaded

Biotech enjoyed a big bounce as investors charged into the market late last week in the belief that the Federal Reserve Board's continued tightening is finally keeping inflation fears in check. Indeed, the BioCentury 100...
08:00 , Dec 7, 1998 |  BioCentury  |  Finance

Immunex blows through the $100 barrier

Immunex (IMNX) surged last week as Chairman and CEO Edward Fritzky told the BancBoston Robertson Stephens conference in New York that the company plans to submit a supplemental NDA with the FDA in the second...
08:00 , Nov 3, 1997 |  BioCentury  |  Finance

Biotech hotbed in Copenhagen

OXFORD - Copenhagen looks poised to become the focus of European IPO activity in 1998. The post-IPO track record of NeuroSearch A/S in the past 15 months - which has seen the value of NEUS...